Orforglipron is no longer a pill people are waiting for. It is now sold as Foundayo, a once-daily prescription GLP-1 pill. GLP-1 is a gut-hormone signal involved in fullness and blood sugar. The FDA authorized Foundayo for chronic weight management on April 1, 2026. It can be taken without planning around food or water, which is its clearest practical difference from oral semaglutide. It is also a new molecule, not semaglutide or tirzepatide in tablet form.
What happened with orforglipron
The FDA announced Foundayo's authorization on April 1, 2026. The agency cleared it for adults with obesity, or adults with overweight and at least one weight-related condition, alongside a reduced-calorie diet and physical activity.
It was the first new molecular entity under the Commissioner's National Priority Voucher program. A new molecular entity simply means the active ingredient had not been authorized before. The FDA said it reached a decision 50 days after filing, far ahead of the original January 2027 target date.
As of September 9, 2026, the day this article was written, Fierce Pharma's Oral GLP-1 Tracker put total weekly prescriptions at roughly 181,000 for the Wegovy pill and 44,000 for Foundayo for the week reported September 4. Both were record highs. Those figures show real interest in pills; they do not tell us which medicine is better for one person.
What orforglipron is
Orforglipron is a GLP-1 receptor agonist, a medicine that copies that gut-hormone signal. It is a small molecule, meaning its chemical structure is compact enough to be absorbed as an ordinary tablet. It is non-peptide, so it is not a chain of amino acids.
That last point solves a stubborn delivery problem. Semaglutide is a peptide, and digestion breaks peptides apart. Its branded tablet therefore uses an absorption enhancer, an added ingredient that helps semaglutide cross the stomach lining. It also comes with an empty-stomach routine and a waiting period before food, drinks or other pills. How oral semaglutide works explains that formulation.
Foundayo's current label, revised in July 2026, says it is taken once daily with or without food. The label has no water-timing restriction. For a wider route comparison, see GLP-1 pills versus injections.
What the trials actually found
ATTAIN-1 followed 3,127 adults with obesity but without diabetes for 72 weeks. Counting everyone originally assigned to treatment, average weight changed by 11.2% at the highest studied amount and by 2.1% with placebo. About 55 in 100 people in that group lost at least 10% of their starting weight. Digestive effects were the most common problems, and 10.3% at the highest amount stopped treatment because of a side effect or other medical problem (Wharton et al., New England Journal of Medicine, 2025).
Lilly's April 1 release led with a different but also valid figure: 12.4% among people who stayed on treatment. The gap is about who gets counted, not a contradiction. For a first-time reader, the 11.2% figure is usually the more cautious number because it keeps everyone who was randomized in the analysis.
ATTAIN-2 studied 1,613 adults who also had type 2 diabetes. At 72 weeks, average weight changed by 9.6% at the highest studied amount and 2.5% with placebo. Treatment stops because of side effects ranged from 6.1% to 9.9% across the orforglipron groups, again mostly because of digestive effects (Horn et al., The Lancet, 2026). Lilly funded both trials.
The safety conversation still matters. The July label lists nausea, constipation, diarrhea and vomiting among the common effects. It also carries warnings about pancreatitis, or inflammation of the pancreas, severe stomach problems, dehydration-related kidney injury, gallbladder disease and low blood sugar when combined with certain diabetes medicines.
The new diabetes data needs context
On June 8, 2026, Lilly released detailed results from three ACHIEVE trials. The most useful comparison was ACHIEVE-3, a head-to-head study of 1,698 adults with type 2 diabetes taking the diabetes medicine metformin.
In the main analysis, A1C, a measure of average blood sugar over roughly three months, fell 1.91 percentage points with the highest orforglipron amount and 1.47 points with the highest oral semaglutide amount after 52 weeks. Digestive effects and treatment stops were more common with orforglipron (Rosenstock et al., The Lancet, 2026).
That is strong comparative diabetes evidence, but it is not a weight-management contest between Foundayo and the Wegovy pill. It also is not a trial against compounded injectable semaglutide or tirzepatide. The current Foundayo label is for chronic weight management, not type 2 diabetes.
What Foundayo changes for someone considering an injection
The biggest change is choice. Foundayo offers a daily tablet without a needle or a fasting routine. Compounded semaglutide and tirzepatide are injections, usually prescribed on a weekly schedule. Tirzepatide also acts on GIP, another hormone signal involved in appetite and blood sugar, while Foundayo and semaglutide act on GLP-1 alone.
The evidence does not let us rank all three as if they were tested in one clean race. Foundayo's obesity trials used its own tablet. The major semaglutide and tirzepatide studies used their manufacturers' products. A compounded formulation is not the product used in those trials.
Foundayo is not a compounded product; it is an FDA-approved brand tablet. Through Promise, semaglutide and tirzepatide are dispensed as compounded medications, which are different from FDA-approved products: the formulations offered here are not FDA-approved.
Regulatory status is one part of the choice. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor. At Promise, a licensed provider reviews every request and prescribes only when medically appropriate; not everyone qualifies.
Why “compounded orforglipron” is a red flag
Compounding means a pharmacy prepares a medication for a patient's specific prescription. It does not mean any new branded drug can be copied and sold at scale.
FDA's April 1, 2026 compounding update says section 503A, the traditional patient-specific route, generally does not cover regular or inordinate amounts of a product that is essentially a copy of a commercially available drug. Under section 503B, the outsourcing-facility route, a bulk ingredient generally must be on the agency's clinical-need list or the drug must be in shortage. These are narrow legal lanes, not a path for a routine Foundayo substitute.
Orforglipron is patent-protected as well. The FDA's July 2026 Orange Book supplement lists a drug-substance and drug-product patent through September 26, 2037, and a five-year new-drug exclusivity period through April 1, 2031. A seller advertising “compounded orforglipron” is not offering the manufacturer tablet and should not be assumed to have recreated it.
What to watch next
The next meaningful update is whether the FDA authorizes Foundayo for type 2 diabetes. Lilly said in its June release that it planned to submit those data, but a study result and an authorized use on the label are different things. The current July label settles what Foundayo is authorized for today.
The next useful real-world number is how many people keep taking it. The September prescription figures show that people are trying both major pills. They cannot yet show how side effects play out outside trials or whether losing the morning fasting routine improves long-term use. Those are the numbers that will make this new choice easier to judge. If the drug names themselves are the hard part, how to pronounce semaglutide walks through the whole GLP-1 family.